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value at the lowest cost, all aspects of the health care system need to
align with patient needs and preferences. Despite growing efforts to
engage patients in research and regulatory activities, the pharma-
ceutical industry has yet to maximize patient involvement in the drug
development process. Objective: To gain a better understanding of
the present state of patient involvement in drug development.
Methods: Through a semistructured interview methodology, we
sought to identify opportunities, barriers, and examples of patient
involvement in the drug development process. Telephone interviews
were conducted with six senior leaders of evidence generation within
the pharmaceutical industry and four patients. These interviews were
supplemented with interviews with a research funder, a regulator, a
patient advocacy group, and a caregiver. Results: Although our
interviewees spoke of the potential beneﬁts of aligning research
around the needs of patients, there were few examples they could
share to suggest this was occurring at scale. A number of barriers were
identiﬁed including the added burden associated with adverse eventee front matter Copyright & 2016, International S
r Inc. This is an open access article under the CC
ons.org/licenses/by-nc-nd/4.0/).http://dx.doi.org/
patientslikeme.com.
ndence to: Maria M. Lowe, PatientsLikeMe, 160 2ndreporting, concerns about patient representativeness or their ability to
participate in drug development conversations, and the costs in time
and resources involved relative to returns on investment. Conclu-
sions: As health care systems continue to evolve and establish
patients as the primary stakeholder in their health care decision
making, the pharmaceutical industry will need to be innovative to
demonstrate the value of their products relative to the outcomes
experienced by patients. Pharmaceutical companies should recognize
the value of involving patients across the entire product life cycle and
work to transform present perceptions and practices throughout their
organizations.
Keywords: decision making, drug development, methodology, patient-
centered.
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Pharmaceutical companies are tasked with developing life-
changing products that meet the needs of patients, physicians,
and payers while adhering to regulatory standards, managing
health technology and payer scrutiny, and performing to satisfy
investors. In addition, in a time when total health care costs are
being scrutinized by government and private payers alike, pro-
viders must maximize the quality of care by using interventions
that provide the most value while minimizing cost. While drug
prices seem to be continually rising, many health plans are
shifting more of the burden of cost sharing to patients. As a
result, the patient is becoming more of a “consumer” in the
traditional sense. This shift demands that the pharmaceutical
industry begin to use the types of consumer research that are a
mainstay of other industries in which the true value of a product
is deﬁned by those who will ultimately use it. Notably, in these
industries, the input of consumers is sought throughout develop-
ment, from product conception through market entry and
beyond.
Developing a treatment that can truly help to improve the
lives of patients should be rooted in a ﬁrm understanding of thechallenges those patients face in their daily lives, their needs,
and the trade-offs they are willing to make to gain relief [1]. To
ensure the creation of valuable treatments, all aspects of the
health care system, including research prioritization, product
development, trial design, regulatory approval, access, reim-
bursement, and treatment decisions, will need to align with the
needs of patients. This realignment has started to take place on
the payer side with the use of health technology assessments
(HTA), which stipulate that patients’ preferences or perspectives
be integrated in value demonstration. Such HTAs are presently in
use in several European countries, and similar value frameworks
are beginning to emerge in the United States, bolstering hopes
that these nascent efforts to increase patient involvement in
various aspects of health care will continue to develop and
expand in scope.
Despite this paradigm shift toward incorporating patient
perspectives, pharmaceutical companies have yet to maximally
engage with patients to learn what they value before developing
a product. Advocacy and market research groups, which have
networks and skills in patient “outreach,” exist in most pharma-
ceutical companies; these departments, however, tend to focus
more on the commercial aspects of launch and postlaunchociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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viduals working in these areas often have different objectives for
engaging with patients than their colleagues in clinical develop-
ment. Because they may also lack the scientiﬁc or technical skill
set necessary to collect patient input in a meaningful way that
will result in actionable insights for their clinical development
programs, many decisions in clinical development are made
without patient input.
At present, limited data exist that describe the scope and
overall beneﬁt of existing patient-centered drug development
activities [2]. Nevertheless, the following story of the inhaled
insulin product Exuberas illustrates how a better understanding
of patient needs can inform the development of a more valuable
product and prevent costly missteps. Exuberas (insulin human
[rDNA origin]) inhalation powder was approved by the Food and
Drug Administration (FDA) in January 2006 for use as a mealtime
insulin, but the makers of the product withdrew it from the
market in October 2007 [3,4]. The goal of this product was to offer
the convenience of an alternative, less invasive route of admin-
istration over injected insulin. Unfortunately, the delivery device
was found to be too cumbersome and patients did not ﬁnd it
appealing enough to stop using injectable insulin. As a result of
the failure to gain the interest of patients and providers, phar-
maceutical company Pﬁzer made the decision to voluntarily
withdraw Exuberas, a decision that cost the company $2.8 billion
[4,5].
Outside the pharmaceutical industry, however, engagement
with patients is increasing. Patients have been invited by regu-
lators such as the FDA, the European Medicines Agency, and the
National Institute for Health and Care Excellence to provide their
perspectives and advice during decision making [6]. In the
Prescription Drug User Fee Act V spanning ﬁscal years 2013 to
2017, the FDA launched the Patient-Focused Drug Development
initiative designed to gain the patient perspective in certain
disease areas and in turn to more effectively inform the FDA’s
evaluation of the risks and beneﬁts of new therapies [7,8]. The
British Medical Journal now includes patients in its peer review
process and encourages authors to coproduce articles with
patients. Researchers submitting grants to the Patient-Centered
Outcomes Research Institute are also encouraged to work with
patients [9,10]. Participant-led research using patient-powered
research networks and social media is challenging our traditional
views of what “a participant” is truly capable of doing [11].
Medical conferences take steps to self-accredit as “#PatientsIn-
cluded™” by involving patients in planning, as presenters, and in
the audience, whereas medical journals can accredit themselves
by inviting patients to join their editorial boards, submit content,
and act as peer reviewers [12]. Such patient-centered activities
differ from mere tokenism [13] because patients themselves are
making decisions with real consequences, instead of merely
being asked for opinions that can be arbitrarily used or ignored
by decision makers.
These efforts to increase patient involvement in various facets
of health care highlight a growing need for the pharmaceutical
industry to shift its approach to proactively engage with patients
during drug development. If pharmaceutical companies remain
unengaged with patients, they risk not only falling behind what
FDA learns as a result of the Patient-Focused Drug Development
initiative but also misunderstanding the concerns of their cus-
tomers and thus ultimately breaking their social contract with
patients [14]. Given the time and money required to develop a
new drug, any misstep is likely to have signiﬁcant ﬁnancial
ramiﬁcations. Because engaging patients in the drug develop-
ment process is not yet commonplace for most pharmaceutical
companies, there is an opportunity to develop recommendations
to guide the inclusion of patients in this process going forward.
To inform the creation of such recommendations, we ﬁrst soughtto learn how patients are presently involved in drug development
and the generation of evidence.Methods
To gain a better understanding of the present state of patient
involvement in drug development, a number of industry, regu-
latory, research, and patient advocacy thought leaders were
interviewed. The interviews aimed to identify previous, present,
and potential areas of patient participation as well as the
corresponding beneﬁts, barriers, and challenges to such patient
involvement. Interviewees were identiﬁed via previous contact
with PatientsLikeMe either as members of the Website or through
personal networks. They were invited to participate with the
understanding that their information would not be attributable to
them personally, that they were free to withdraw at any time,
and that they would receive no compensation except early access
to a ﬁnal report. To guide the conversation, each interview was
conducted using a semistructured interview format over approx-
imately 60 minutes using the questions and topics listed in
Appendices I and II in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2016.04.009. Key themes for health care
thought leaders included the interviewee’s experience with
including patient voice in drug development, their feelings about
the role patients could potentially play in different aspects of
development, speciﬁc examples including what worked well and
what did not, and potential challenges and barriers to incorpo-
rating patient voice. Key themes for patients included their
experience of working with researchers and with other stake-
holders such as the FDA, their thoughts on the skills needed to be
effective, and their thoughts for the future of patient engagement
in drug development. Interviews were conducted between June
2014 and August 2015. The authors compiled transcripts and
analyzed major themes and concepts upon completion of all
interviews.Results
A total of 14 interviews were conducted: 8 with health care
thought leaders, 5 with patient thought leaders, and 1 with a
disease-speciﬁc patient advocacy foundation. For the purposes of
this analysis, the results of the interview with the patient
advocacy foundation will be included with those of the patient
interviews because all these interviewees represented patient
interests. Of the 8 health care thought leaders interviewed, six
worked in the pharmaceutical industry, one for a regulatory
agency, and one for a research institute. Interviewees of the
pharmaceutical industry were at either the vice president or
director level and represented various departments, including
health economics and outcomes research, medical evidence,
global outcomes, epidemiology, evidence science and innovation,
patient-reported outcomes (PROs), and research integration. Of
the ﬁve patient thought leaders interviewed, all represented the
experience of patients with incurable, chronic illnesses with
signiﬁcant impact on daily life.
Health Care Thought Leader Interviews
Our health care interviewees all expressed the belief that incor-
porating the patient voice into drug development and evidence
generation is a positive development. They reasoned that “being
more patient-centric is always a good thing,” particularly as a
way to better understand heterogeneity of disease and identify
unmet needs: “Patients often bring a refreshing perspective on
what matters… things that doctors might not have talked about.”
Our interviewees felt that incorporating the patient voice into
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bility to do right by patients, but it can help inform the develop-
ment of important therapeutics and even help avoid costly
missteps in the development process.
The industry interviewees identiﬁed ﬁve main areas in which
patients are presently involved: informing product strategy,
informing clinical trial design, developing PROs, generating evi-
dence, and participating in company/regulatory meetings. The
interviewees were able to cite a number of speciﬁc examples, but
also stated that these represented exceptions rather than estab-
lished practice, and patient input was not incorporated consis-
tently. The interviewees also provided a number of areas in
which patients could potentially be better involved in the drug
development process (Table 1).
In contrast, the regulator and research funder we spoke to
both worked at organizations that took a systematic approach to
including patients throughout the research process. Training was
included to increase skills and build the capacity of patients to
contribute. In some cases, patients had speciﬁc responsibilities
such as writing reports, reviewing grants, writing lay summaries,
or conducting their own research studies. Both organizations
were funded by national governments and had requirements for
patient inclusivity explicitly written into their mandates.
The health care thought leader interviewees cited a number of
barriers and challenges to expanding patient involvement in drug
development (Table 2). Two of the greatest challenges identiﬁedTable 1 – Present and potential future areas of patient in
generation process, as described by health care thought
Focus area Present examples of patient involveme
Product strategy  Small number of invited patients participate in
groups to inform product strategy
 Product development teams hold meetings wi
patient advocacy groups during product develo
process
Clinical trials  Patients may be called upon to provide input o
protocols and study design, particularly if
recruitment is going poorly
 Patients may provide qualitative feedback
throughout trial participation that is fed back
company via health care professionals
PRO development
activities
 Patients participate in activities such as qualit
interviews and concept elicitation
Evidence
generation
 Patients participate in clinical trials or have th
health care claims data analyzed
 Patients’ burden-of-illness assessments
Patients as
meeting
participants
 Patients may speak at company meetings to h
the tone and provide employees with the patie
perspective
 Patients may be included as full voting memb
regulatory committee meetings
PRO, patient-reported outcome.were timing and budget impact. Legal, compliance, and regula-
tory challenges were also frequently mentioned by industry
representatives when it came to talking to patients: “We can talk
about patients, but not with patients.” One interviewee cited an
example when their company convened an advisory board that
included patients; the interviewee recalled that industry col-
leagues found it hard to move past the concern that they were
“somehow breaking the law by having patients in the room.”
Another common theme was that the pharmaceutical industry
and other health care decision makers, such as physicians, are
slow to adapt and often resist change to the status quo. Those
who endorse expanding patient involvement in drug develop-
ment activities have an uphill battle to enact change. Last,
concerns were expressed regarding the lack of evidence to
suggest that patient participation in drug development would
deliver sufﬁcient tangible beneﬁts to justify the costs, expressed
in terms of sufﬁcient “return on investment.”
Patient Thought Leader Interviews
In addition to various members of the health care industry, we
interviewed ﬁve patient thought leaders and one patient advo-
cacy organization to gain their perspectives. In general, these
interviewees reported sensing an increased desire on the part of
drug developers to include patients, but reported that signiﬁ-
cant progress is needed. They all emphasized that whatevervolvement in the drug development and evidence
leader interviewees.
nt Future potential for patient involvement
focus  Gather input more uniformly from patients (including
their experiences, needs, and expectations) and
quantitatively assess their needs and insights to guide
the product agenda
th
pment
n trial  Include patients as partners in the process charged
with ensuring patient centricity of study protocols,
study hypotheses, recruitment materials, and end
point selection to increase patient interest in
participating, and avoid problems with study
recruitment and retention
to the
 Leverage patients outside of the clinical trial setting
to better understand the real-world settings patients
live in
 Systematically listen to patients participating in
clinical trials to better manage the trial and inform
further development
ative  Include patients as partners in the design of PRO
instruments
 Provide patients self-monitoring PRO tools outside of
clinical trial context to better manage their conditions
eir  Develop tools to support participant-led research
 Increase connectivity between patients and medical/
pharmacy claims data or health care use to support
economic modeling
 Involve patients in evidence dissemination to their
peers
elp set
nt
 Utilize appropriate training and safeguards, and
recruit patients as pharmaceutical staff to serve as
company employees and internal subject matter
experts to change culture from the insideers in
Table 2 – Barriers to increasing the level of patient
involvement in the drug development process, as
described by health care thought leader
interviewees.
Timing and budget concerns
 Unknown return on investment for increasing patient
involvement
 IRB approval
 Rapidity of drug development
Compliance and regulatory challenges
 Adverse event reporting
 No industry guidance on interacting with patients
 Regulators slow to adopt patient-generated data and real-world
data
 No regulatory requirement to involve patients in the drug
development and evidence generation process
Methodological challenges
 Lack of uniform, repeatable, scientiﬁcally rigorous methods for
involving patients
 Clinical trials may become unblinded
 Patient views may conﬂict with regulators, clinicians, and
scientists
Organizational and clinical inertia
 If it is not broken, why ﬁx it?
 Existence of inconsistent practices within and across companies
 Clinicians and researchers resistant to change
 Development and validation of PROs slow and expensive
 Uncertainty regarding feasibility of involving patients
 Uncertainty regarding ideal methods for involving patients
Negative perceptions about patients’ ability to participate
 Belief that patients cannot be representative as a result of being
biased by their own experiences (in contrast to key opinion
leaders who might have cared for hundreds or even thousands
of patients)
 Patients do not always have the knowledge required to
participate in complex drug development conversations
IRB, institutional review board; PRO, patient-reported outcome.
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patients are eager and willing to be involved but they need to
be invited to the table. One interviewee described it not as patient
involvement or engagement, but as patient integration: “Invite me
to be on your team … Show me that you appreciate and value
me.” Another felt that patients and drug developers are both
interested in the same things: “We all want better treatments
developed more quickly.”
One of the most prominent themes present was that patients
should be involved from the start. It is too late to bring a patient
in at the end to simply react to or sign off on work that was done
without them. The interviewees felt this could be improved by
getting patients involved in setting the research agenda and
product development plan for a given product or disease state:
“Patients should be engaged early and often and there is a place
at each step from conception all the way to FDA approval.”
Interviewees felt that patient involvement does not mean having
patients necessarily inform the science behind drug development,
but rather it should focus on the experiences of patients living with
an illness. Patients are best suited to provide insight regarding their
perceptions of beneﬁts and risks, relevance of an issue being studied,
what symptoms matter most, and overall impact on daily life. One
patient commented, “It just seems kind of funny to me that you can
go through the whole process of getting a clinical trial underway and
never include a patient in the process.” Patients felt that decision
makers, particularly regulators, do not always have a completeunderstanding of the risks that patients with some illnesses are
willing to accept, and that this beneﬁt-risk assessment will vary by
disease. Patients also expressed that they may be willing to accept
more risks to get the right treatment sooner.Discussion
We sought to characterize the present state of patient involve-
ment in drug development to inform the development of a set of
recommendations to aid pharmaceutical companies in more
proactive and consistent engagement of patients. The results of
our interviews revealed little evidence that patients are routinely
involved during drug development or that their involvement in
the drug development process is widely sought beyond a few
champions. Some of the examples of patient involvement pro-
vided by our interviewees would sit quite low on Arnstein’s
ladder of citizen participation [13], frequently cited by the
Patient-Centered Outcomes Research Institute as a useful frame-
work to understand engagement. For example, involving patients
as participants in research studies to better understand their
disease for PRO development is, at best, consultative rather
than a reﬂection of true partnership. Inviting patients to act as
speakers at meetings may have the appearance of patient
centricity, but this risks co-opting the experience of patients to
boost morale without actually inviting them to participate in
decision making.
Our interviews also conﬁrmed the existence, whether real or
perceived, of many of the same barriers to consistent patient
involvement in drug development identiﬁed by Hoo et al. [1],
such as inconsistency and fragmentation of approach. The health
care thought leader interviewees cited a range of concerns, not
least of which was the widespread perception by employees of
pharmaceutical companies that patient interaction constitutes a
regulatory violation. Some concerns shared regarding this issue
represent real challenges, such as the need to report adverse
events reported by patients, whereas others were representative
of more imagined barriers, such as regulatory or legal statutes
prohibiting direct interactions with patients.
These ﬁndings support the notion that the availability of
existing engagement frameworks has not been sufﬁcient to
encourage and inform more widespread patient involvement in
drug development; thus, the creation and validation of such a
framework is an important next step to guide the development of
better drug products [1,15,16]. For any proposed framework to be
successful, it needs to be speciﬁc in identifying areas of the drug
development process in which patients can become more
involved, it needs to describe and recommend how patients
could become involved in such activities, and it needs to be
accepted by all stakeholders in this process [1]. Drawing upon
what was learned from these health care and patient thought
leader interviews, we would like to propose a framework for
increasing patient involvement in drug development, beginning
with the principles outlined in Table 3.
On the basis of the ﬁndings of our patient thought leader
interviews, we support the recommendation to use the phrase
“patient involvement,” because it conveys a more active role on
the part of the patient [1]. By deﬁning what constitutes patient
involvement at the company level, drug developers can then
create company-speciﬁc values and priorities for including
patients as partners throughout this process. We recognize that
for meaningful patient involvement to become more common-
place, real and perceived barriers—structural, cultural, and regu-
latory—will need to be overcome. At present, patient
involvement is not uniformly recognized as valuable in drug
development by those in the pharmaceutical industry. This is
why we feel it is important for leadership within companies to
Table 3 – Principles for increasing patient involvement in drug development.
 Acknowledge the importance of patient involvement and deﬁne what it means to truly incorporate patients as partners.
 Take inventory: Review existing efforts and work with patients to determine when patients should be more included.
 Be transparent: Own up to instances when this could have been done better, both internally and to external stakeholders such as patients,
payers, and regulators.
 Trust patients: Invest in them and take the time to educate them on issues and needs.
 Involve patients continuously, early, and often: Encourage involvement across all phases of product development.
 Treat patients as collaborators: They should be seen and treated as equal stakeholders and not as a target market.
 Display leadership: Be ambassadors for this cause for the rest of the industry.
 Be the change you want to see: Proactively provide patient-generated perspectives and evidence to regulators, payers, and market access
gatekeepers.
 Share your lessons learned: Document failures as well as successes.
 Collaborate to develop best practices: Share tool kits with your peers.
Table 4 – Barriers and proposed solutions for increasing the level of patient involvement in the drug
development process.
Barrier Example(s) Solution(s)
Timing and budget concerns  Providing sufﬁcient support for patient
involvement increases time and resources
needed for development of the speciﬁc studies,
thereby prolonging drug development and
increasing costs.
 Factor these additional costs in earlier, model the
potential beneﬁts later down the line in terms of
approval or trial accrual—“You save time by
making time.” By involving patients early and
often throughout drug development (speciﬁcally
in the design of clinical trials), time may
ultimately be saved by preventing difﬁculty with
recruiting and retaining patients in clinical trials.
Compliance and regulatory
challenges
 Concerns over adverse event reporting
requirements and the lack of regulatory guidance
on interacting with patients.
 Pharmaceutical companies can create an open
dialogue with regulators to avoid pitfalls, model
engagement on existing mechanisms, and
develop best practices.
Methodological challenges  Concerns on both sides about “tokenism” or
“nonparticipating observers of technical
discussions.”
 Ensure that patients are included in decisions as
equal partners and ensure they see rapid
evidence of their efforts. Proactively solicit
patient feedback and respect the thoughts and
opinions they provide.
 Patient partners may have strong opinions that
are not scientiﬁcally feasible (e.g., breaking
equipoise).
 Be open and honest with patients about what is
expected of them and about the potential impact
that their input can have. Treat them as a valued
partner in the process. Be honest and
transparent if feedback is provided that would
not be directly actionable. Do not dismiss
patients as not helpful and address potential
conﬂicts or differences of understanding
constructively.
 Concerns about external validity of involved
patient group to wider population.
 Develop a set of patient characteristics of
importance for the issue at hand to guide
population selection or try to match patient
participants against best available
epidemiological data for the patient population.
 One patient may not be representative enough.  For many drug development activities, it may
make sense to include more than one patient.
Involving more than one patient in each activity
may increase patient comfort in taking a more
active role. Patients serving as the sole
representative of their disease community may
not feel valued or supported and this may
negatively impact their ability to be productive
participants in these processes.
 Regardless of the number of patients involved,
encourage each to connect with others in their
disease community to gain more insight into the
experience and opinions of others. Patients are
likely making these connections with one
continued on next page
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Table 4 – continued
Barrier Example(s) Solution(s)
another already; encouraging such connections
can provide an additional source of learning and
maximize the impact of involving a small
number of patients in drug development.
 Uncertainty regarding how to ﬁnd the right
patients.
 Develop “personas” describing the types of
patients who could be helpful across the entire
drug development process for a given disease
state and narrow patient selection on the basis of
these personas and the speciﬁc activity that
patients will be getting involved in. Using these
personas, drug developers can adopt an
approach similar to empaneling a jury to identify
a small, but representative, patient sample.
 Some characteristics to look for in patients who
will thrive when taking on a more active role
include training from an advocacy group
regarding drug development or research
processes, comfort with public speaking, comfort
with voicing opinions in group meetings, and
basic understanding of study design and drug
development.
 Patients are ready and willing to help and there
are plenty of advocacy groups and patient
interest organizations that are available to help
prepare patients for this role and facilitate
connections. These organizations can also
provide expertise and guidance with respect to
working with patient representatives and may
even offer various training programs to prepare
patients for the various roles they may play in
the drug development and research processes.
 Getting the right information from patients.  Trust patients. Do not assume they are not
capable of understanding what they need to.
Invest in them and take the time to educate
them on issues they need to understand to
become involved in various activities.
 Make questions answerable; keep them simple
and remove ambiguity.
 Ask the right questions and be ready to listen. If
you ask the right questions, patients will answer
them. Even if a patient is not skilled in science/
research, there are still things that can be
learned by speaking with them about the right
things. Patients have valuable insight into their
experiences, regardless of the questions being
asked.
 Use both qualitative and quantitative methods to
collect information from patients. Quantitative
techniques will allow you to measure trends but
qualitative methods will help inform further
dialogue with patients.
 Researchers may inﬂuence involved patients to
further own agenda.
 Patient selection could be tasked to a neutral
third party such as a nonresearcher or patient.
Similarly, such third parties could be used to
guide and facilitate patient discussions if
concerns exist regarding the partiality of
researchers or other members on the drug
development team.
Organizational and clinical
inertia
 Patient involvement is not as great a “win” as
other methods of protocol optimization (e.g., six
sigma).
 Patient involvement does not preclude other
forms of trial improvement research and should
focus on framing questions rather than serving
as the sole technique for optimizing solutions.
continued on next page
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Table 4 – continued
Barrier Example(s) Solution(s)
 Researchers are interested primarily in
optimizing trials and not involving patients in
earlier phases of decision making such as
outcome selection.
 Start small and build in more patient
involvement over time. For example, begin with
trial optimization as the ﬁrst project that
patients are involved in and in subsequent
projects “back the truck up” to get patients
involved earlier in the drug development
process, as mutual trust and success build up.
 Resistance to change on the part of drug
developers, researchers, and clinicians.
 Train the drug-developing and medical
communities to change their way of thinking when
it comes to patient perspective. Teach them the
value of including patients and lead by example.
When it comes to pharmaceutical companies, the
change needs to come from the top down and be
fully supported throughout the organization.
Negative perceptions about
patients’ ability to
participate
 Patients require careful induction and
onboarding.
 Develop an intake interview so that patients can
meet with someone who will be involved in the
rest of their participation to outline expectations
and offer information tailored to areas in which
they will be participating and not just the whole
program of work.
 Low population health literacy/lack of knowledge
or understanding of the intricacies of research
design and drug development processes.
 Careful selection, mentoring, and patient
education programs in advance of involvement
activities but also investigator education in
communication. Nevertheless, just because
patients may not know the details of drug
development or research processes does not
preclude them from being helpful.
 Patients may not always know how to answer
technically complex questions, but it should be
more about ﬁnding a way to listen to them share
their own stories and experiences.
 Patients themselves are unavailable because of
consent or cognitive capacity issues.
 Involve caregivers or patient advocates on their
behalf; recruit early-stage or high-functioning
patients when possible.
 Language/cultural issues.  Use extra resources for translation and cultural
sensitivity training.
 Patients move or are lost to follow-up.  Maintain strong bonds within the community to
maintain contact; use multiple channels for
working with patients (e.g., in person meetings,
teleconferences, and electronic
communications).
 Patients might not be capable of being “objective”
or representative of the patient experience
beyond their own.
 Involve more than one patient in the various
parts of this process to ensure that you can
obtain more than one opinion/experience.
Patient experiences may vary, but after talking to
a group of patients, patterns and themes will
begin to emerge.
 Acknowledge that nobody at the table now is
truly objective; the industry wants proﬁt,
researchers want results. Furthermore, patient
bias toward their needs is not bias: it is a ﬁnding.
Learning about the experience of individual
patients is an important part of understanding
the overall patient experience and unmet needs
of a speciﬁc disease community.
 Contextual factors (e.g., work, culture, and
religion) inhibit participation of certain group
members.
 Use multichannel interaction to account for
individual constraints and adopt culturally
sensitive facilitation practices.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 6 9 – 8 7 8 875champion this effort and to be the change that they wish to see.
This leadership needs to be focused both internally to all aspects
of company operations and externally to set an example forothers within the industry. We believe that it is equally important
that payers and HTAs give adequate weight to patient prefer-
ences in their valuation of treatments. Doing so will likely serve
Table 5 – A potential approach to including patients in pharmaceutical companies inspired by
PatientsIncluded (note that all criteria must be satisﬁed).
Criteria Existing PatientsIncluded criteria for
medical conferences [12]
Existing PatientsIncluded
criteria for medical
journals [12]
Potential equivalents for
pharmaceutical companies
1 Patients or caregivers with experience
relevant to the conference’s central
theme actively participate in the design
and planning of the event, including the
selection of themes, topics, and speakers.
At least two patients sit on the
editorial board of the
journal.
All members of the CEO’s leadership team
are accountable for integrating patient
views into decision making for their
respective functional areas. These are
captured in company and functional
scorecards.
2 Patients or caregivers with experience of
the issues addressed by the event
participate in its delivery and appear in
its physical audience.
Patients routinely publish
content in the journal as
authors of editorials,
reviews, or research articles.
Company creates a “patient council”
composed of patients experienced with
relevant therapeutic areas, which reports
to the board and is accountable for the
progress of patient centricity through key
metrics.
3 Travel and accommodation expenses for
patients or caregivers participating in the
advertised program are paid in full in
advance. Scholarships are provided by
the conference organizers to allow
patients or caregivers affected by the
relevant issues to attend as delegates.
Patients serve as peer
reviewers of submissions to
the journal.
The patient council creates standard
operating procedures to incorporate
patient and caregiver input into relevant
internal decision-making bodies to
provide their perspective at the point of
decision making (e.g., ﬁnal protocol
approval and patient service program
approval).
4 The disability requirements of participants
are accommodated. All applicable
sessions, breakouts, ancillary meetings,
and other program elements are open to
patient delegates.
The journal is an open access
publication, with no barriers
to access full- text content.
The patient council has appropriate
internal resources in place to allow
internal teams to appropriately access
patient and caregiver perspectives to
generate patient insight and cocreate
patient solutions with patients.
5 Access for virtual participants is facilitated,
with free streaming video provided
online whenever possible.
The company’s approach to integrating
patients as a part of their team is
detailed in the company’s scorecard, key
metrics, and each year in the company’s
annual report to shareholders.
CEO, chief executive ofﬁcer.
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 6 9 – 8 7 8876as an incentive for pharmaceutical companies to face these
barriers head on and involve patients in drug development
activities in meaningful ways.
Best practices for patient involvement are still in development
and further experimentation will be required to identify what
techniques work best. Companies will need to experiment with
different methods to learn what works best and try to build on
the successes of others in the industry [17]. Pharmaceutical
companies have an opportunity to achieve a strategic advantage
by building internal expertise of the most impactful strategies for
patient involvement, to guide development of industry best
practices, and to anticipate changes to regulatory requirements.
To help facilitate these changes, we have also proposed a
range of solutions to overcome the barriers identiﬁed by our
interviewees (Table 4). It is important to note that patient
involvement may take many forms: patients may serve on
advisory boards during protocol development, provide guidance
on early product development strategies or speciﬁc areas of
clinical trial protocols, serve as coinvestigators, and coauthor
articles. Inspired by the work of the PatientsIncluded group,
which invites voluntary self-accreditation against a crowd-
sourced set of criteria, we also propose some practical steps that
senior leadership could take within their organization today to
bring patients into their business as true partners (Table 5) [12].
Although patient involvement is a valuable resource during
many stages of evidence generation, it may not always be practicalto include it in all decisions. For example, patients may not be
needed for determining targets for “technical” attributes such as
biomarkers or surrogate markers. Nevertheless, a mutual under-
standing of the technical aspects of the product development
process that cannot be altered, such as the delivery mechanism of
a medication or clinical trial end points established by regulators,
and why these cannot be altered, is essential to the creation of an
engagement process that produces meaningful feedback.
The European Patients’ Academy on Therapeutic Innovation
has been established to help address such gaps in knowledge or
understanding. By partnering a number of nonproﬁt, academic,
and patient organizations with a number of European pharma-
ceutical companies, the European Patients’ Academy on Ther-
apeutic Innovation seeks to train and educate patients and
provide the support and resources needed so that they can be
more directly involved in the drug development process [18].
Recognizing that there is no equivalent organization in the
United States at present, one way to overcome such challenges
is for drug developers to partner with patient advocacy organ-
izations and interest groups. These entities have a great deal of
experience in working with patients and may be best suited to
connect drug developers with patients who are ready and willing
to play a larger role. One such organization, the Parkinson’s
Disease Foundation, offers specialized training programs to
provide patients the skills and knowledge they need to take a
more active role in research [19].
• Discuss with researchers what research is important to the disease community 
• Develop study concept and work as a coinvestigator with disease specialists 
• Assist in grant writing at local research center 
• Serve as a grant reviewer 
• Become a grant reviewer with the Patient-Centered Outcomes Research Institute 
• Provide input on study design such as barriers to participation or study end points 
• Join an Institutional Review Board 
• Help finalize eligibility criteria within the study protocol 
• Assist in creating the informed consent form 
• Advise and assist with study recruitment 
• Serve as a peer advocate during the informed consent process 
• Join a Data Safety Monitoring Board 
• Provide recommendations for revising study protocol if changes need to be made 
• Provide feedback on how the disease community will view the study results 
• Write newsletter articles or blog about results 
• Copresent results at a conference or support group 
• Work with research team to ensure study participants get feedback from study 
• Apply to be a consumer representative to a US Food and Drug Administration (FDA) Advisory Committee 
• Attend FDA hearings and provide comment 
• Advocate for continued tracking of drugs, devices, and therapies 
• Work with researchers to integrate patient-centered outcomes in research  
Develop the 
Study 
Concept
Secure
Funding (if 
applicable)
Prepare the 
Study 
Protocol
Create Study 
Procedure
Implement 
the Study
Monitor the 
Study
Analyze Data 
and Interpret 
Results
Disseminate 
Study 
Information
FDA review 
and Approval
Post-approval 
studies
Fig. 1 – Potential areas of patient involvement throughout the drug development cycle. Adapted with permission from the
Parkinson’s Disease Foundation.
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work for how patients can be involved in the various stages of
drug development [19]. Taking what was learned from our
interviewees, this framework has been adapted and is presented
in Figure 1. Patients can and should be involved in drug develop-
ment from the very beginning. Our patient thought leaders
stressed that it is not just about ﬁnding a drug that is safe and
effective, but rather ﬁnding one that truly meets the needs of
patients. Without including patients in this conversation early
on, it will be difﬁcult to fully understand those needs and thetrade-offs that patients are willing to make. Patients’ perspectives
on disease burden, treatment experience, risk-beneﬁt assess-
ments, and unmet needs may be incorporated early, informing
the drug discovery phase or during the shaping of the target
product proﬁle (TPP). The TPP is a strategic guidance used by
pharmaceutical sponsors to facilitate discussions and solicit
feedback from regulators on the overall drug development pro-
gram for an investigational product [20]. Among other things in a
TPP, the patient voice can inform product attributes such as the
route of administration, dosing, efﬁcacy, acceptable levels of
V A L U E I N H E A L T H 1 9 ( 2 0 1 6 ) 8 6 9 – 8 7 8878adverse events, and possibly even willingness to pay. Such an
approach will lead to the development of a patient-centric TPP
that reﬂects patients’ burden of disease, perspective on disease
severity, and experience with existing treatment options. Com-
panies should seek patient input in developing the TPP and
continually engage patients to update this throughout the
remainder of the drug development process. This will help the
organization in identifying suitable criteria and metrics in shap-
ing their products, which, in turn, will steer drug development
toward medications that address how patients function and feel,
including their quality of life and unmet medical needs. We
believe that this investment will lead not only to a drug proﬁle
that resonates with unmet patient needs but also to an increased
likelihood of favorable reimbursement decisions.
Beyond the TPP, patients could be involved in activities related
to clinical trials such as study conception by outlining their needs
and priorities; protocol advisement through consultation on the
logistics of study design, the appropriateness of inclusion/exclu-
sion criteria, and patient willingness to adhere; advisement on the
selection of devices used in trials (if applicable); and consultation
on informed consent and whether it is clear enough.
As with any research, the approach described here has some
limitations. It is important to recognize the relatively small
number of interviews conducted and that our samples for each
cohort are not representative of all health care or patient thought
leaders, which could mean that not all the barriers to increasing
patient involvement were identiﬁed. Furthermore, we do not
have speciﬁc evidence to support the effectiveness of the recom-
mendations presented. More evidence is needed to support the
theorized positive return on investment in increasing patient
involvement in drug development. Further research should focus
on evaluating the impact and effectiveness of these recommen-
dations or any other efforts to better involve patients in drug
development. This evidence will provide the insight needed to
take the next step toward establishing industry-wide best prac-
tices. Although we recognize that additional work will need to be
done to build on the recommendations outlined here and develop
a concrete and consistent methodology that can be used by all
drug developers, we hope that these proposals can facilitate and
encourage such efforts.Conclusions
Along with widespread efforts to curb health care spending, the
advent of formal HTAs and payer evaluations for formulary and
reimbursement positioning has created the need for drug devel-
opers to demonstrate value to obtain reimbursement for their
products. Because the cost and beneﬁt of a treatment are ulti-
mately, either directly or indirectly, realized by patients, their input
is essential to develop medications that encompass value.
The results of our interviews highlighted a common interest in
increasing patient involvement in drug development activities, but
made it clear that there is work to do before this becomes a reality.
If the pharmaceutical industry is to truly partner with patients, a
number of key cultural and logistical barriers within organizations
will have to be overcome. Leadership within pharmaceutical
companies must recognize the value of patient engagement across
the entire product life cycle and work to transform present
perceptions throughout their organizations. Because this industry
has a history of being ﬁnancially successful, it might be considered
“safe” to point to present practices as sufﬁcient to maintain their
viability. Just because shareholders are doing well does not mean
that it has been truly successful or has done right by patients. It is
time to redeﬁne what it means to succeed in the drug develop-
ment industry and how to create products of value.Acknowledgments
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